MRKR · Marker Therapeutics, Inc.
AI read · Good for MRKR
The AI's read
The grant gives Marker outside money to advance MT-601 without issuing shares. That can help pay for its next study. Earlier results showed responses, but they came from only 12 patients. The planned Phase 2 study has yet to confirm those results.